Mineralys Reports Positive Clinical Data for Lorundrostat in Heart Failure Risk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Mineralys Therapeutics reported positive post hoc data from the Phase 3 Launch-HTN and Phase 2b Advance-HTN trials, based on 1,004 participants, indicating that Lorundrostat significantly reduces heart failure risk biomarkers, highlighting its potential in hypertension treatment.
- Biomarker Changes: The findings revealed that Lorundrostat increased renin levels and decreased angiotensinogen, demonstrating effective engagement with the renin-angiotensin-aldosterone system (RAAS), which provides new insights for managing heart failure risk.
- Heart Failure Risk Indicators: Lorundrostat significantly reduced six candidate biomarkers associated with heart failure risk, including NT-proBNP, supporting its application potential in heart failure treatment and laying the groundwork for further clinical evaluation.
- Market Reaction: Mineralys shares closed at $23.62, down 1.34%, but rose to $25.00 in after-hours trading, up 5.84%, reflecting a positive market response to the new data.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLYS
Wall Street analysts forecast MLYS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.940
Low
46.00
Averages
52.60
High
56.00
Current: 23.940
Low
46.00
Averages
52.60
High
56.00
About MLYS
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lorundrostat Significantly Reduces Heart Failure Risk Biomarkers
- Reduction in Heart Failure Biomarkers: A proteomic analysis of participants with uncontrolled hypertension revealed that lorundrostat significantly reduced six candidate causal biomarkers of heart failure, including NT-proBNP, suggesting its potential to modulate physiological processes related to heart failure through RAAS inhibition, thereby providing new biological plausibility for heart failure treatment.
- Clinical Trial Data Support: In the Launch-HTN and Advance-HTN trials involving 1,004 participants, lorundrostat treatment resulted in significant increases in renin and decreases in angiotensinogen, reflecting effective engagement with the RAAS, further validating its potential application in managing heart failure risk.
- FDA Review Process: Lorundrostat is currently under review by the U.S. FDA, with a target decision date of December 22, 2026, which is crucial for its market potential and the company's future growth trajectory.
- Economic Burden of Hypertension: Hypertension was a primary or contributing cause in over 685,000 deaths in the U.S., with related health issues resulting in an estimated annual economic burden of about $219 billion, highlighting the urgent need for effective treatments like lorundrostat, especially for patients with uncontrolled and resistant hypertension.
See More
Mineralys Reports Positive Clinical Data for Lorundrostat in Heart Failure Risk
- Clinical Trial Results: Mineralys Therapeutics reported positive post hoc data from the Phase 3 Launch-HTN and Phase 2b Advance-HTN trials, based on 1,004 participants, indicating that Lorundrostat significantly reduces heart failure risk biomarkers, highlighting its potential in hypertension treatment.
- Biomarker Changes: The findings revealed that Lorundrostat increased renin levels and decreased angiotensinogen, demonstrating effective engagement with the renin-angiotensin-aldosterone system (RAAS), which provides new insights for managing heart failure risk.
- Heart Failure Risk Indicators: Lorundrostat significantly reduced six candidate biomarkers associated with heart failure risk, including NT-proBNP, supporting its application potential in heart failure treatment and laying the groundwork for further clinical evaluation.
- Market Reaction: Mineralys shares closed at $23.62, down 1.34%, but rose to $25.00 in after-hours trading, up 5.84%, reflecting a positive market response to the new data.
See More
Mineralys Therapeutics Prices Stock Offering at $26.50
- Stock Offering Pricing: Mineralys Therapeutics has priced an offering of 5.66 million shares at $26.50 each, with gross proceeds expected to be around $150 million, enhancing the company's liquidity for future growth.
- Clear Use of Proceeds: The net proceeds from this offering will fund a portion of the $200 million upfront payment for repurchasing royalty obligations under its license agreement with Tanabe Pharma, ensuring financial stability in key partnerships.
- Timely Offering Schedule: The sale is expected to close on or about June 4, 2026, subject to customary closing conditions, demonstrating the company's strategic timing and meticulous planning in capital raising.
- Strong Underwriter Lineup: BofA Securities, Goldman Sachs, and Evercore ISI are acting as joint book-running managers for the offering, indicating strong market confidence in the transaction and the company's influence in capital markets.
See More
Mineralys Therapeutics Prices $150 Million Underwritten Offering
- Offering Size: Mineralys Therapeutics announced the pricing of 5,660,378 shares at $26.50 each, expecting gross proceeds of approximately $150 million, which will significantly bolster the company's funding for its research and development initiatives.
- Use of Proceeds: The net proceeds from this offering will be allocated towards a $200 million upfront payment for repurchasing royalty obligations under its license agreement with Tanabe Pharma Corporation, thereby alleviating financial burdens and enhancing market competitiveness.
- Debt Financing: Mineralys also revealed a $500 million committed debt facility with Pharmakon Advisors, LP, which will provide additional financial security for its future operations and research, further supporting its drug development efforts in hypertension and related diseases.
- Market Response: The successful pricing of this offering reflects strong market confidence in Mineralys, which is expected to enhance its stock performance and lay a solid foundation for the company's long-term growth in the biopharmaceutical sector.
See More
Velan Capital Reduces Stake in Mineralys Therapeutics
- Stake Reduction: According to an SEC filing dated May 15, 2026, Velan Capital sold 140,000 shares of Mineralys Therapeutics in Q1, with an estimated transaction value of $4.11 million, indicating a cautious outlook on the company's future prospects.
- Decline in Position Value: Following the sale, Velan Capital's position value decreased by $5.18 million, reflecting the dual impact of trading activities and stock price changes, suggesting a weakening market confidence in Mineralys.
- Current Holdings: As of quarter-end, Velan Capital holds 11,000 shares of Mineralys valued at $297,990, with this stake now representing only 0.19% of its total assets under management, thus falling outside its top five holdings.
- Financial Status Analysis: Mineralys reported a loss of $39.3 million in Q1, but with $646 million in cash on hand, it should be able to sustain operations while the FDA reviews its lorundrostat application, although the lack of approved products poses ongoing risks.
See More
Velan Capital Reduces Stake in Mineralys Therapeutics
- Share Reduction Details: According to an SEC filing dated May 15, 2026, Velan Capital sold 140,000 shares of Mineralys Therapeutics in Q1, valued at approximately $4.11 million, leaving it with 11,000 shares worth about $297,990, resulting in a net position decline of $5.18 million due to both share sales and price fluctuations.
- Holding Proportion Change: Following this reduction, Mineralys Therapeutics now represents only 0.19% of Velan Capital's reportable U.S. equity AUM, indicating a waning confidence in the company, while its top holdings include PRAX, TARA, and STRO.
- Market Performance Analysis: As of May 14, 2026, Mineralys Therapeutics shares were priced at $27.27, reflecting an 80.5% increase over the past year, significantly outperforming the S&P 500 by 53.18 percentage points, showcasing its strong position in the biopharmaceutical market.
- FDA Review Progress: Mineralys's lead product candidate, lorundrostat, is currently under FDA review, with an expected approval decision by December 22, 2026, which could present significant market opportunities for the company, despite reporting a loss of $39.3 million in Q1 and having no approved products yet.
See More
Lorundrostat Significantly Reduces Heart Failure Risk Biomarkers
- Reduction in Heart Failure Biomarkers: A proteomic analysis of participants with uncontrolled hypertension revealed that lorundrostat significantly reduced six candidate causal biomarkers of heart failure, including NT-proBNP, suggesting its potential to modulate physiological processes related to heart failure through RAAS inhibition, thereby providing new biological plausibility for heart failure treatment.
- Clinical Trial Data Support: In the Launch-HTN and Advance-HTN trials involving 1,004 participants, lorundrostat treatment resulted in significant increases in renin and decreases in angiotensinogen, reflecting effective engagement with the RAAS, further validating its potential application in managing heart failure risk.
- FDA Review Process: Lorundrostat is currently under review by the U.S. FDA, with a target decision date of December 22, 2026, which is crucial for its market potential and the company's future growth trajectory.
- Economic Burden of Hypertension: Hypertension was a primary or contributing cause in over 685,000 deaths in the U.S., with related health issues resulting in an estimated annual economic burden of about $219 billion, highlighting the urgent need for effective treatments like lorundrostat, especially for patients with uncontrolled and resistant hypertension.
See More
Mineralys Reports Positive Clinical Data for Lorundrostat in Heart Failure Risk
- Clinical Trial Results: Mineralys Therapeutics reported positive post hoc data from the Phase 3 Launch-HTN and Phase 2b Advance-HTN trials, based on 1,004 participants, indicating that Lorundrostat significantly reduces heart failure risk biomarkers, highlighting its potential in hypertension treatment.
- Biomarker Changes: The findings revealed that Lorundrostat increased renin levels and decreased angiotensinogen, demonstrating effective engagement with the renin-angiotensin-aldosterone system (RAAS), which provides new insights for managing heart failure risk.
- Heart Failure Risk Indicators: Lorundrostat significantly reduced six candidate biomarkers associated with heart failure risk, including NT-proBNP, supporting its application potential in heart failure treatment and laying the groundwork for further clinical evaluation.
- Market Reaction: Mineralys shares closed at $23.62, down 1.34%, but rose to $25.00 in after-hours trading, up 5.84%, reflecting a positive market response to the new data.
See More
Mineralys Therapeutics Prices Stock Offering at $26.50
- Stock Offering Pricing: Mineralys Therapeutics has priced an offering of 5.66 million shares at $26.50 each, with gross proceeds expected to be around $150 million, enhancing the company's liquidity for future growth.
- Clear Use of Proceeds: The net proceeds from this offering will fund a portion of the $200 million upfront payment for repurchasing royalty obligations under its license agreement with Tanabe Pharma, ensuring financial stability in key partnerships.
- Timely Offering Schedule: The sale is expected to close on or about June 4, 2026, subject to customary closing conditions, demonstrating the company's strategic timing and meticulous planning in capital raising.
- Strong Underwriter Lineup: BofA Securities, Goldman Sachs, and Evercore ISI are acting as joint book-running managers for the offering, indicating strong market confidence in the transaction and the company's influence in capital markets.
See More
Mineralys Therapeutics Prices $150 Million Underwritten Offering
- Offering Size: Mineralys Therapeutics announced the pricing of 5,660,378 shares at $26.50 each, expecting gross proceeds of approximately $150 million, which will significantly bolster the company's funding for its research and development initiatives.
- Use of Proceeds: The net proceeds from this offering will be allocated towards a $200 million upfront payment for repurchasing royalty obligations under its license agreement with Tanabe Pharma Corporation, thereby alleviating financial burdens and enhancing market competitiveness.
- Debt Financing: Mineralys also revealed a $500 million committed debt facility with Pharmakon Advisors, LP, which will provide additional financial security for its future operations and research, further supporting its drug development efforts in hypertension and related diseases.
- Market Response: The successful pricing of this offering reflects strong market confidence in Mineralys, which is expected to enhance its stock performance and lay a solid foundation for the company's long-term growth in the biopharmaceutical sector.
See More
Velan Capital Reduces Stake in Mineralys Therapeutics
- Stake Reduction: According to an SEC filing dated May 15, 2026, Velan Capital sold 140,000 shares of Mineralys Therapeutics in Q1, with an estimated transaction value of $4.11 million, indicating a cautious outlook on the company's future prospects.
- Decline in Position Value: Following the sale, Velan Capital's position value decreased by $5.18 million, reflecting the dual impact of trading activities and stock price changes, suggesting a weakening market confidence in Mineralys.
- Current Holdings: As of quarter-end, Velan Capital holds 11,000 shares of Mineralys valued at $297,990, with this stake now representing only 0.19% of its total assets under management, thus falling outside its top five holdings.
- Financial Status Analysis: Mineralys reported a loss of $39.3 million in Q1, but with $646 million in cash on hand, it should be able to sustain operations while the FDA reviews its lorundrostat application, although the lack of approved products poses ongoing risks.
See More
Velan Capital Reduces Stake in Mineralys Therapeutics
- Share Reduction Details: According to an SEC filing dated May 15, 2026, Velan Capital sold 140,000 shares of Mineralys Therapeutics in Q1, valued at approximately $4.11 million, leaving it with 11,000 shares worth about $297,990, resulting in a net position decline of $5.18 million due to both share sales and price fluctuations.
- Holding Proportion Change: Following this reduction, Mineralys Therapeutics now represents only 0.19% of Velan Capital's reportable U.S. equity AUM, indicating a waning confidence in the company, while its top holdings include PRAX, TARA, and STRO.
- Market Performance Analysis: As of May 14, 2026, Mineralys Therapeutics shares were priced at $27.27, reflecting an 80.5% increase over the past year, significantly outperforming the S&P 500 by 53.18 percentage points, showcasing its strong position in the biopharmaceutical market.
- FDA Review Progress: Mineralys's lead product candidate, lorundrostat, is currently under FDA review, with an expected approval decision by December 22, 2026, which could present significant market opportunities for the company, despite reporting a loss of $39.3 million in Q1 and having no approved products yet.
See More
